Vnitr Lek 2019, 65(12):770-774 | DOI: 10.36290/vnl.2019.134

Vascular age

Ondřej Petrák, Richard Češka*
III. interní klinika - klinika endokrinologie a metabolizmu 1. LF UK a VFN v Praze

Age can be evaluated according to many criteria. Of course the objective measure is the calendar age which may differ from the biological age. The biological age more or less correlates with the vascular age. The concept of vascular age is based on the statement that "An individual is as old as his blood vessels". The process of vascular aging already starts in childhood. Arterial aging may essentially be viewed from two standpoints. First, it involves stiffening of arteries and loss of their elasticity; second, degenerative changes and formation of atherosclerotic plaques occur, being the cause of ischemia, especially in case of the development of atherothrombosis. Both these processes can be monitored: The change of elasticity (arteriosclerosis) mainly by examination of pulse wave velocity (PWV), atherosclerosis then primarily with non-invasive methods, ultrasound or CT angiography examination. From the clinical point of view it is particularly important whether we can influence vascular age in some way. Evidence is available now that atherosclerosis can be affected by hypolipidemic treatment, arteriosclerosis then in particular by ACE inhibitors. The aforementioned possibility of influencing vascular age brings us to another problem, which is compliance of patients. With regard to that it is good that in a situation where we have two drugs affecting vascular age, we can use their fixed combination. It is available as a combination of atorvastatin and perindopril.

Keywords: ACE inhibitors; atorvastatin; CT angiography; dyslipidemia; hypertension; intima media thickness (IMT); perindopril; pulse wave velocity (PWV); statins; vascular age

Received: October 24, 2019; Accepted: November 12, 2019; Published: December 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Petrák O, Češka R. Vascular age. Vnitr Lek. 2019;65(12):770-774. doi: 10.36290/vnl.2019.134.
Download citation

References

  1. American Heart Association (2014). Why Cholesterol Matters. Dostupné z WWW: <http://www.heart.org/HEARTORG/Conditions/Cholesterol/WhyCholesterolMatters/Why-Cholesterol-Matters_UCM_001212_Article.jsp>. [07-2015].
  2. Halcox JP, Tubach F, Lopez-Garcia E et al. Low Rates of Both Lipid-Lowering Therapy Use and Achievement of Low-Density Lipoprotein Cholesterol Targets in Individuals at High-Risk for Cardiovascular Disease across Europe. PLoS One 2015; 10(2): e0115270. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0115270>. Go to original source... Go to PubMed...
  3. Gaede P, Lund-Andersen H, Parving HH et al. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. N Engl J Med 2008; 358(6): 580-591. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0706245>. Go to original source...
  4. Jimenez JG, Rosen JB, Pirags V et al. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome. Diabetes Obes Metab 2013; 15(6): 513-522. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12059>. Go to original source... Go to PubMed...
  5. Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1563-1574. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1001282>. Go to original source... Go to PubMed...
  6. Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia 2013; 56(4): 686-695. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125-012-2817-5>. Go to original source... Go to PubMed...
  7. Watts GF, Ooi EM. Balancing the cardiometabolic benefits and risks of statins. Lancet 2012; 380(9841): 541-543. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(12)61301-4>. Go to original source... Go to PubMed...
  8. Van Bortel LM, Laurent S, Boutouyrie P et al. [European Society of Hypertension Working Group on Vascular S, Function, European Network for Noninvasive Investigation of Large Arteries]. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens 2012; 30(3): 445-448. Dostupné z DOI: <http://dx.doi.org/10.1097/HJH.0b013e32834fa8b0>. Go to original source... Go to PubMed...
  9. O'Rourke M. Mechanical principles in arterial disease. Hypertension 1995; 26(1): 2-9. Dostupné z DOI: <http://dx.doi.org/10.1161/01.hyp.26.1.2> Go to original source... Go to PubMed...
  10. [Reference Values for Arterial Stiffness' Collaboration]. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J 2010; 31(19): 2338-2350. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehq165>.
  11. Laurent S, Marais L, Boutouyrie P. The Noninvasive Assessment of Vascular Aging. Can J Cardiol 2016; 32(5): 669-679. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cjca.2016.01.039>. Go to original source... Go to PubMed...
  12. Laurent S, Boutouyrie P, Asmar R et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37(5): 1236-1241. Dostupné z DOI: <http://dx.doi.org/10.1161/01.hyp.37.5.1236>. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.